Status of, and strategies for improving, adherence to HCC screening and surveillance
| Autor: | Giampiero Francica, Mauro Borzio |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Cirrhosis business.industry Cancer medicine.disease digestive system diseases 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Hepatocellular carcinoma Nonalcoholic fatty liver disease medicine Etiology 030211 gastroenterology & hepatology business Alpha-fetoprotein Cause of death Subclinical infection |
| Zdroj: | Journal of Hepatocellular Carcinoma. 6:131-141 |
| ISSN: | 2253-5969 |
| Popis: | Hepatocellular carcinoma (HCC) represents the second leading cause of cancer deaths worldwide and the main cause of death in patients with cirrhosis. Secondary prevention of HCC can be accomplished through the serial application of screening tests (ultrasound with or without alpha-fetoprotein) to detect the presence of subclinical lesions amenable to potentially curative treatment, such as surgery and ablation. The efficacy of HCC screening is accepted by hepatologists in terms of decline in cancer-specific mortality, but its translation into clinical practice is less than ideal. The effectiveness of HCC screening is hampered by several factors: failure to identify at-risk patients, failure to access care and failure to detect HCC. For each of these steps, possible improvements are discussed in order to face the changing etiology of cirrhosis and expand the screening of at-risk populations by including selected nonalcoholic fatty liver disease patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|